Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Venture Technologies Sdn Bhd, Bavarian Nordic AsfiledCriticalVenture Technologies Sdn Bhd
Priority to MYPI20023973priorityCriticalpatent/MY145463A/en
Publication of MY145463ApublicationCriticalpatent/MY145463A/en
Micro-Organisms Or Cultivation Processes Thereof
(AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents
(AREA)
Abstract
THE PRESENT INVENTION RELATES TO NS1 PROTIENS OR PARTS THEREOF OF FLAVIVIRUSES, IN PARTICULAR OF DENGUE VIRUSES USEFUL FOR VACCINATION AGAINST SAID FLAVIVIRUS AND AGAINST ONE OR MORE OTHER FLAVIVIRUSES. THE INVENTION FUTHER CONCERS THE NS1 PROTIEN OR PARTS THEREOF OF ONE DENGUE VIRUS SEROTYPE, IN PARTICULAR SEROTYPE 2, USEFUL FOR VACCINATION AGAINST DENGUE VIRUSES FROM ALL SEROTYPES. THE INVENTION FUTHER CONCERS DNA COMPRISING AN EXPRESSION CASSETTE CODING FOR A FLAVIVIRUS NS1 OR PARTS THEREOF, VECTORS COMPRISING SAID DNA AND VACCINES CONTAINING OR EXPRESSING A FLAVIVIRUS NS1.
Dengue tetravalent vaccine containing a common 30 nucleotide deletion in the 3'-utr of dengue types 1,2,3, and 4, or antigenic chimeric dengue viruses 1,2,3, and 4
Use of flaviviruses for the expression of protein epitopes and for the development of a novel live attenuated vaccine virus for immunization against flaviviruses and other infectious agents.
Polyprotein, nucleic acid molecule, plasmid, recombinant vaccine or attenuated vaccine, pharmaceutical composition, and method for immunizing an individual against HIV.